BUFFALO, NY--(Marketwire - July 08, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today that its first patent for Protectan CBLB502 was granted by the Eurasian Patent Organization (EAPO), which includes nine member countries. This patent covers the method of protecting a mammal from radiation using flagellin or its derivatives, including Protectan CBLB502.